

Maartje Ca Wouters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/397103/publications.pdf>

Version: 2024-02-01

17
papers

1,214
citations

687363

13
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

2476
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 6125-6135.	7.0	287
2	Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. <i>Breast Cancer Research</i> , 2012, 14, R34.	5.0	168
3	A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon- γ 2b in patients with recurrent epithelial ovarian cancer. <i>Annals of Oncology</i> , 2015, 26, 2141-2149.	1.2	144
4	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 784-796.	3.4	141
5	CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. <i>European Journal of Cancer</i> , 2016, 60, 1-11.	2.8	125
6	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580.	7.0	79
7	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCR β ^{hi} CD8 β ^{hi} T cells that can be targeted for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 75130-75144.	1.8	64
8	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 714-724.	7.0	51
9	Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4089-4100.	7.0	46
10	Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. <i>Oncolmmunology</i> , 2014, 3, e962397.	4.6	27
11	C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. <i>MAbs</i> , 2015, 7, 321-330.	5.2	22
12	The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. <i>Gynecologic Oncology</i> , 2020, 158, 167-177.	1.4	20
13	CD20 ⁺ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. <i>Oncolmmunology</i> , 2015, 4, e999536.	4.6	17
14	Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. <i>Oncolmmunology</i> , 2020, 9, 1760705.	4.6	11
15	Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 520-529.	1.4	10
16	Size matters: Survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation. <i>Oncolmmunology</i> , 2016, 5, e1122863.	4.6	2
17	The MOCOG study: Learning from extraordinary responders to improve treatment outcomes for women with ovarian cancer. <i>Pathology</i> , 2020, 52, S30-S31.	0.6	0